NO994898L - Cytomodulering av lipofile peptider for å modulere immunsystemaktivitet og inhibere inflammasjon - Google Patents

Cytomodulering av lipofile peptider for å modulere immunsystemaktivitet og inhibere inflammasjon

Info

Publication number: NO994898L
Authority: NO; Norway
Prior art keywords: cells; activity; lymphocytic; inhibiting; inhibit
Prior art date: 1997-04-11

Application number

NO994898A

Other languages

English (en)

Other versions

NO994898D0 (no

Inventor

Roland Buelow

Gerard Grassy

Bernard Calas

Original Assignee

Sangstat Medical Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-11

Filing date

1999-10-08

Publication date

1999-11-24

1998-02-23 Priority claimed from US09/028,083 external-priority patent/US6696545B1/en

1999-10-08 Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp

1999-10-08 Publication of NO994898D0 publication Critical patent/NO994898D0/no

1999-11-24 Publication of NO994898L publication Critical patent/NO994898L/no

Links

206010061218 Inflammation Diseases 0.000 title 1
230000005965 immune activity Effects 0.000 title 1
230000004054 inflammatory process Effects 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
239000000203 mixture Substances 0.000 abstract 5
230000000527 lymphocytic effect Effects 0.000 abstract 4
102000004127 Cytokines Human genes 0.000 abstract 3
108090000695 Cytokines Proteins 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 3
230000002401 inhibitory effect Effects 0.000 abstract 3
102000004190 Enzymes Human genes 0.000 abstract 2
108090000790 Enzymes Proteins 0.000 abstract 2
150000003278 haem Chemical class 0.000 abstract 2
230000002757 inflammatory effect Effects 0.000 abstract 2
230000028709 inflammatory response Effects 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
102000015636 Oligopeptides Human genes 0.000 abstract 1
108010038807 Oligopeptides Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000000735 allogeneic effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
238000004590 computer program Methods 0.000 abstract 1
230000009089 cytolysis Effects 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

NO994898A 1997-04-11 1999-10-08 Cytomodulering av lipofile peptider for å modulere immunsystemaktivitet og inhibere inflammasjon NO994898L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US83891697A	1997-04-11	1997-04-11
US09/028,083 US6696545B1 (en)	1997-04-11	1998-02-23	Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
PCT/US1998/007231 WO1998046633A1 (en)	1997-04-11	1998-04-10	Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation

Publications (2)

Publication Number	Publication Date
NO994898D0 NO994898D0 (no)	1999-10-08
NO994898L true NO994898L (no)	1999-11-24

Family

ID=26703275

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO994898A NO994898L (no)	1997-04-11	1999-10-08	Cytomodulering av lipofile peptider for å modulere immunsystemaktivitet og inhibere inflammasjon

Country Status (14)

Country	Link
US (1)	US7267822B2 (no)
EP (1)	EP0973799B1 (no)
JP (1)	JP4550171B2 (no)
CN (1)	CN1216900C (no)
AT (1)	ATE352556T1 (no)
AU (2)	AU761717B2 (no)
BR (1)	BR9808529B1 (no)
CA (1)	CA2286478A1 (no)
IL (1)	IL132310A0 (no)
NO (1)	NO994898L (no)
NZ (1)	NZ500287A (no)
PL (1)	PL336302A1 (no)
TR (1)	TR199902786T2 (no)
WO (1)	WO1998046633A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2773240B1 (fr)	1997-12-30	2002-11-29	Synt Em	Procede pour prevoir, identifier et decrire des molecules susceptibles de presenter un comportement recherche, notamment dans le domaine de la pharmacie et molecules obtenues par ce procede
AU4650500A (en) *	1999-04-21	2000-11-02	Baylor College Of Medicine	Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis
WO2003061602A2 (en)	2002-01-24	2003-07-31	Sangstat Medical Corporation	Combination therapy for treatment of hiv infection
IL163718A0 (en) *	2002-02-26	2005-12-18	Ngstat Medical Corp	Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy
FR2842738B1 (fr) *	2002-07-23	2006-02-10	Negma Lerads	Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus
RU2005118425A (ru) *	2002-11-15	2006-02-10	Сэнгстат Медикал Корпорейшн (Us)	Цитомодуляторные пептиды для лечения интерстициального цистита
WO2005009457A1 (en) *	2003-05-15	2005-02-03	Sangstat Medical Corporation	Rdp58 compositions and methods for inhibiting vascularization of cell populations
WO2005001075A1 (en) *	2003-05-15	2005-01-06	Sangstat Medical Corporation	Rdp58 compositions and methods for modulating the activity of osteoclasts and osteoblasts
US7498309B2 (en)	2003-11-29	2009-03-03	Sangstat Medical Corporation	Pharmaceutical compositions for bioactive peptide agents
CN104231054A (zh) *	2014-09-01	2014-12-24	王跃建	Il-10多肽抑制剂
GB201918167D0 (en) *	2019-12-11	2020-01-22	Univ Newcastle	Collagen production

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5888512A (en) *	1987-01-30	1999-03-30	Board Of Trustees Of The Leland Stanford Junior University	Lymphocyte activity regulation by HLA peptides
AU619458B2 (en)	1987-01-30	1992-01-30	Board Of Trustees Of The Leland Stanford Junior University	Lymphocyte inhibition by hla peptides
US5723128A (en) *	1987-01-30	1998-03-03	The Board Of Trustees Of The Leland Stanford Junior University	Cytotoxic T-cell lymphocyte ("CTL") activity regulation by class I MHC peptides
US5385888A (en) *	1987-03-20	1995-01-31	The Regents Of The University Of California	Class I MHC modulation or surface receptor activity
WO1990010016A1 (en)	1989-03-03	1990-09-07	The Regents Of The University Of California	Class i mhc modulation of surface receptor activity
CA2115839C (en) *	1991-08-26	2010-06-01	Maria A. Vitiello	Hla-restricted hepatitis b virus ctl epitopes
EP0661985B1 (en)	1991-11-08	1999-07-07	The Board Of Trustees Of The Leland Stanford Junior University	Peptides capable of binding cd8 molecules on ctl precursors
US5440015A (en)	1992-07-21	1995-08-08	Glycomed Incorporated	Selectin peptide medicaments for treating disease
US6828415B2 (en) *	1993-02-19	2004-12-07	Zentaris Gmbh	Oligopeptide lyophilisate, their preparation and use
JPH09508617A (ja) *	1993-11-10	1997-09-02	ザボードオブトラスティーズオブザリーランドスタンフォードジュニアユニバーシティ	表面膜タンパク質および免疫応答に対するそれらの影響
US5707622A (en) *	1994-03-03	1998-01-13	Genentech, Inc.	Methods for treating ulcerative colitis
AU694602B2 (en) *	1995-01-16	1998-07-23	Northern Sydney And Central Coast Area Health Service	Novel peptide
US6162434A (en) *	1995-05-03	2000-12-19	Sangstat Medical Corporation	Cytomodulating peptide for inhibiting lymphocyte activity
US5753625A (en) *	1995-05-12	1998-05-19	Sangstat Medical Corporation	Treatment for inhibiting the progression of autoimmune disease
WO1997024140A1 (en)	1996-01-02	1997-07-10	The Board Of Trustees Of Leland Stanford Junior University	Interaction of hla proteins with members of the hsp70 family of proteins
US6436903B1 (en)	1996-05-22	2002-08-20	Stanford University (Board Of Trustees Of The Leland Standford Junior University)	Immunomodulating compounds comprising d-isomers of amino acids
WO1997044351A1 (en)	1996-05-24	1997-11-27	The Board Of Trustees Of Leland Stanford Junior University	Immunomodulating dimers
US6696545B1 (en) *	1997-04-11	2004-02-24	Sangstat Medical Corporation	Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation

1998
- 1998-04-10 CN CN98806071XA patent/CN1216900C/zh not_active Expired - Fee Related
- 1998-04-10 CA CA002286478A patent/CA2286478A1/en not_active Abandoned
- 1998-04-10 AT AT98914676T patent/ATE352556T1/de not_active IP Right Cessation
- 1998-04-10 NZ NZ500287A patent/NZ500287A/xx not_active Application Discontinuation
- 1998-04-10 WO PCT/US1998/007231 patent/WO1998046633A1/en not_active Ceased
- 1998-04-10 BR BRPI9808529-8A patent/BR9808529B1/pt not_active IP Right Cessation
- 1998-04-10 EP EP98914676A patent/EP0973799B1/en not_active Expired - Lifetime
- 1998-04-10 TR TR1999/02786T patent/TR199902786T2/xx unknown
- 1998-04-10 JP JP54410298A patent/JP4550171B2/ja not_active Expired - Fee Related
- 1998-04-10 PL PL98336302A patent/PL336302A1/xx not_active Application Discontinuation
- 1998-04-10 IL IL13231098A patent/IL132310A0/xx unknown
- 1998-04-10 AU AU68978/98A patent/AU761717B2/en not_active Ceased
1999
- 1999-10-08 NO NO994898A patent/NO994898L/no not_active Application Discontinuation
2003
- 2003-09-05 AU AU2003244571A patent/AU2003244571B2/en not_active Ceased
2004
- 2004-02-17 US US10/780,321 patent/US7267822B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ATE352556T1 (de)	2007-02-15
AU2003244571A1 (en)	2003-10-02
EP0973799B1 (en)	2007-01-24
US20040248810A1 (en)	2004-12-09
CN1259958A (zh)	2000-07-12
AU6897898A (en)	1998-11-11
EP0973799A1 (en)	2000-01-26
PL336302A1 (en)	2000-06-19
TR199902786T2 (xx)	2000-06-21
NO994898D0 (no)	1999-10-08
AU2003244571B2 (en)	2007-07-05
NZ500287A (en)	2002-10-25
WO1998046633A1 (en)	1998-10-22
US7267822B2 (en)	2007-09-11
BR9808529A (pt)	2000-10-24
BR9808529B1 (pt)	2010-10-05
JP2001526641A (ja)	2001-12-18
AU761717B2 (en)	2003-06-05
JP4550171B2 (ja)	2010-09-22
CA2286478A1 (en)	1998-10-22
CN1216900C (zh)	2005-08-31
IL132310A0 (en)	2001-03-19

Publication	Publication Date	Title
TR199801168T2 (xx)	1998-09-21	�nterleukin-1 beta d�n��t�r�c� enzim inhibit�rleri.
DE69435171D1 (de)	2009-01-08	Pan dr-bindeproteinen zur erhöhung der immunantwort
AU9315398A (en)	1999-03-29	Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
EA199700135A1 (ru)	1997-12-30	Ингибиторы клеточной адгезии
BR9811956B1 (pt)	2010-06-01	naftiridinonas e composição farmacêutica compreendendo as mesmas.
ATE270557T1 (de)	2004-07-15	Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
PL348147A1 (en)	2002-05-06	Utilisation of dialkylfumarates
NO994898L (no)	1999-11-24	Cytomodulering av lipofile peptider for å modulere immunsystemaktivitet og inhibere inflammasjon
TR199802136T2 (xx)	2001-06-21	�MPDH enzimi inhibit�rleri olarak �re t�revleri.
TR200001982T2 (tr)	2001-02-21	Farmasötik vurulu salınımlı oral dozaj şekli.
RU95108217A (ru)	1997-06-10	Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
ATE63748T1 (de)	1991-06-15	Enzymwiderstandsfaehige immunomodulatorische peptide.
DK0643726T3 (da)	2000-03-20	Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
NO992463D0 (no)	1999-05-21	N-(aryl/heteroarylacetyl)aminosyreestere, farmas°ytiske sammensetninger som omfatter det samme, og metoder for inhibering av <beta>-amyloidpeptidfrigivelse og/eller dens syntese ved bruk av slike forbindelser
YU61502A (sh)	2006-03-03	Nukleozidni analozi karboksamidno modifikovanih bicikličnih baza
EA200100732A1 (ru)	2002-02-28	Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию
RU94041224A (ru)	1995-09-10	Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
DE60017141D1 (de)	2005-02-03	Replikationskompetente anti-tumor vektoren
DK0633763T3 (da)	1997-12-29	Kosmetiske eller farmaceutiske sammensætninger indeholdende deacylerede glycerophospholipider til topisk brug
PT1276763E (pt)	2004-06-30	Proteinas anti-congelantes sua producao e utilizacao
RU99107658A (ru)	2001-02-20	Применение белков в качестве агентов против аутоиммунных заболеваний
DE69807672D1 (de)	2002-10-10	Von milchsäure abgeleitete butyrat-prodrugs
NO942228L (no)	1994-12-16	Ipsapiron-legemiddeltilberedning
SE8701457D0 (sv)	1987-04-07	Immunostimulerande tripeptider
Zaroukian	1986	SURFACE LY-5 GLYCOPROTEIN IN MURINE NATURAL KILLER (NK) CELL DEVELOPMENT, TARGET BINDING AND CYTOTOXICITY: FUNCTIONAL STUDIES AND PRELIMINARY BIOCHEMICAL CHARACTERIZATION.

Legal Events

Date	Code	Title	Description
2006-11-20	FC2A	Withdrawal, rejection or dismissal of laid open patent application